Welcome to our dedicated page for TScan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.
The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.
TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.
In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.
For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.
TScan Therapeutics (Nasdaq: TCRX) announced its participation in the Jefferies Global Healthcare Conference, scheduled for June 5, 2024, at 11:00 a.m. ET at the Marriott Marquis in New York, NY. The company, which is focused on developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, will present during the conference. A live webcast of the presentation will be available on TScan's website, with a replay accessible for 90 days post-event.
TScan Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead TCR-T therapy candidates, TSC-100 and TSC-101, for treating heme malignancies, including AML, ALL, and MDS. The RMAT designation is based on encouraging data from the ALLOHA trial and aims to expedite the development of transformative therapies. Both candidates target minor histocompatibility antigens HA-1 and HA-2 to eliminate malignant cells in patients undergoing allogeneic HCT with reduced intensity conditioning. Initial trial data show promising results with no relapse in treated patients and no dose-limiting toxicities observed.
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results for Q1 2024, dosing the first patient in its Phase 1 solid tumor program. All Phase 1 heme program patients remain relapse-free. A public offering raised $167.8 million, extending funds into Q4 2026. The company presented at major medical meetings and plans poster presentations at ASCO. TScan aims to advance heme and solid tumor programs with upcoming milestones.
TScan Therapeutics announced the dosing of the first patient in a Phase 1 clinical trial for TCR-T therapy targeting solid tumors, with initial data expected in 2024. The company aims to expand its ImmunoBank to enhance multiplex TCR-T therapy for solid tumors.
FAQ
What is the current stock price of TScan Therapeutics (TCRX)?
What is the market cap of TScan Therapeutics (TCRX)?
What is TScan Therapeutics, Inc.?
What are TScan's leading therapy candidates?
What recent recognition has TScan's therapies received?
What types of cancer does TScan focus on?
How does TScan aim to improve cancer treatment?
How can I contact TScan's Investor Relations?
Where can I get the latest updates about TScan?
What is the stock symbol for TScan Therapeutics, Inc.?
Who are the key contacts for media inquiries at TScan?
What are TScan's goals in immunotherapy?
